A new citrated formulation of nalidixic acid (Mictral U.K.) for the treatment of acute cystitis.
A 3-day course of a new citrated formulation of nalidixic acid (Mictral) was assessed in fifty-four women presenting with acute uncomplicated cystitis. Over 96% of women with a significant Gram-negative bacteriuria were cured of the infection following a course of treatment. Only two relapses occurred in this group during the follow-up period. Relief of symptoms occurred in nearly 90% of infected patients and generally by the second day of treatment. Although the incidence of side-effects was about 20% they were not considered serious.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009268:Nalidixic Acid / Q000627:therapeutic use*
D009268:Nalidixic Acid